throbber
Br. J. Pharmacol. (I 993), 110, 772 776
`
`Br. J. Pharmacot. (1993), 110, 772 776
`
`'PI Macmillan Press Ltd, 1993
`
`Macmillan Press Ltd, 1993
`
`Effect of a calcitonin gene-related peptide antagonist
`(CGRP8-37) on skin vasodilatation and oedema induced by
`stimulation of the rat saphenous nerve
`K. Jane Escott & 'Susan D. Brain
`
`Pharmacology Group, Division of Biomedical Sciences, King's College, Manresa Road, London SW3 6LX
`
`1 The effect of the calcitonin gene-related peptide antagonist (CGRP837, 400 nmol kg-', i.v.) on the
`increased blood flow induced by calcitonin gene related peptide (CGRP), vasodilator prostaglandins,
`and topical capsaicin was measured with a laser Doppler blood flow meter in rat abdominal skin.
`2 The saphenous nerve was electrically stimulated and the effect of CGRP8-37 (400 nmol kg-', i.v.) on
`the increased blood flow (measured by laser Doppler flowmetry) and oedema formation (measured by
`the extravascular accumulation of ['25f]-albumin) was investigated in the rat hind paw.
`CGRP8-37 (400 nmol kg-', i.v.) had no effect on basal cutaneous blood flow at uninjected sites and
`3
`sites injected with Tyrode buffer, but acted selectively to inhibit the increased blood flow induced by
`intradermal CGRP (10 pmol/site, P< 0.05), but not that induced by prostaglandin E2 (PGE2, 300 pmol/
`site) or carba-prostacyclin (cPGI2, 100 pmol/site).
`Capsaicin (0.1-33 mM), applied topically, acted in a dose-related manner to increase blood flow.
`4
`CGRP837 (400 nmol kg-', i.v.) almost totally inhibited blood flow induced by capsaicin (10 mM;
`P <0.05) but did not significantly inhibit blood flow induced by a higher dose of capsaicin (33 mM).
`5 The increased blood flow induced by short stimulation of the saphenous nerve (10 V, 1 ms, 2 Hz for
`30 s) was inhibited by 76%, 5 min after i.v. CGRP837 (400 nmol kg-', i.v., P<0.05).
`6 A longer (5 min) electrical stimulation of the saphenous nerve caused oedema formation, in addition
`to increased blood flow. The oedema formation was significantly inhibited by CGRP8-37 (400 nmol kg-',
`i.v., P<0.05).
`7 The results suggest that the potent microvascular vasodilator neuropeptide, CGRP, is responsible for
`the increased blood flow observed after short stimulation of the saphenous nerve and that endogenous
`CGRP contributes in a pro-inflammatory manner to neurogenic oedema formation in the rat hind paw.
`Keywords: Calcitonin gene-related peptide (CGRP); substance P; neurokinin-1 receptors; saphenous nerve; skin blood flow;
`laser Doppler flowmetry; neurogenic inflammation
`
`Introduction
`
`Our group has previously studied the release and activity of
`the 37 amino acid vasodilator sensory neuropeptide cal-
`citonin gene-related peptide (CGRP) in the rabbit cutaneous
`microvasculature. The studies show that the increased blood
`flow induced in rabbit skin by intradermal injection of cap-
`saicin and analogues (e.g. olvanil), can be inhibited by the
`co-injection of the 8-37 amino acid C-terminal peptide of
`CGRP (CGRP8-37), a selective competitive antagonist of
`CGRP (Chiba et.al., 1989; Gardiner et al., 1990; Han et al.,
`1990). Early experiments suggested that CGRP8-37 could par-
`tially
`inhibit capsaicin-induced vasodilatation (Hughes &
`Brain, 1991), whilst more recent experiments using CGRP8-37
`synthesized by improved techniques have shown that a 60%
`increase in blood flow in response to capsaicin (100 nmol/
`site) is totally inhibited by CGRP8-37 (Hughes et al., 1992).
`We have concluded from these results that CGRP is an
`important vasodilator neuropeptide released from capsaicin
`sensitive nerves in rabbit skin. It is generally assumed that
`substance P, which is often co-localised with CGRP also has
`an important vasoactive effect. However, substance P is an
`extremely weak vasodilator in rabbit skin (Brain et al., 1985)
`and a neurokinin-I (NK,) receptor selective antagonist had
`little effect on capsaicin-induced blood flow in this species
`(Hughes et al., 1992).
`In this study we have investigated the release and activity
`of CGRP in rat skin, where neurokinins (especially substance
`P) have been established as potent vasoactive mediators
`(Lembeck & Holzer 1979; Gamse & Saria 1985; Brain &
`
`'Author for correspondence.
`
`Williams 1989). We know, from a previous study that
`CGRP8-37 cannot be administered intradermally in the rat due
`to a pro-inflammatory activity, possibly related to basic
`residues in the N-terminus region (Brain et al., 1992). Thus
`we have administered CGRP8-37 intravenously (i.v.) which has
`been shown to be effective in inhibiting the hypotensive
`effects of i.v. CGRP in several studies (Donoso et al., 1990;
`1990). We have examined the ability of
`Gardiner et al.,
`influence the sensory nerve-dependent pro-
`CGRP8-37 to
`inflammatory responses in the rat in response to capsaicin
`administration and electrical stimulation of the saphenous
`nerve.
`
`Methods
`
`Blood flow and oedema formation were measured in the skin
`of male Wistar rats (200-300 g), anaesthetized with sodium
`pentobarbitone (Sagatal, May and Baker, initial i.p. injection
`50-80 mg kg-', maintained by additional 20 mg kg- h-',
`given i.v.). Body temperature was maintained at 36-38°C by
`automatic control of a heating pad. Rats were pretreated
`with guanethidine (20mgkg-', s.c.) 24h before saphenous
`nerve stimulation, to prevent vasoconstriction induced by
`concomitant stimulation of the sympathetic fibres of the
`saphenous nerve (Gamse & Saria, 1987).
`
`Measurement of bloodflow in abdominal skin
`The animal was anaesthetized, and the abdominal skin
`
`1
`
`EX2007
`Eli Lilly & Co. v. Teva Pharms. Int'l GMBH
`IPR2018-01427
`
`

`

`CGRP RELEASE FROM SAPHENOUS NERVE
`
`773
`
`Materials
`The following drugs were used: prostglandin El (PGEI) from
`Sigma Chemical Company, U.K., human a-calcitonin gene-
`related peptide (CGRP) a gift from Dr U. Ney, Celltech,
`U.K., human CGRP8-37 from Bachem, U.K.,
`synthetic
`vanillylamide
`from
`capsaicin-pelargonic
`acid
`Fluka
`Chemicals Ltd., U.K., carba-prostacyclin (cPGI2) from Cas-
`cade Biochem. Ltd., U.K., and guanethidine from Ciba-
`Geigy, U.K. CGRP, PGE, and PGI2 were stored in stock
`solutions at - 20°C and then diluted with Tyrode solution
`immediately prior to use. CGRP837 was prepared in 0.1%
`bovine serum albumin (BSA) in saline. Capsaicin was dis-
`solved in ethanol at 100 mg ml-' and diluted in a solution of
`alcohol:Tween 80:saline, at a ratio of 20:10:70. '25I-labelled
`human serum albumin was obtained from Amersham Inter-
`national, U.K. Immac (Reckitt & Colman, U.K.) was used to
`remove remaining hair stubble. The composition of the
`Tyrode solution was a follows (mM): NaCl 136.89, KCI 2.68,
`NaH2PO4 0.42, NaHCO3 11.9, MgCl2 1.05 and glucose 5.55.
`
`Results
`
`The intradermal injection of CGRP, PGE, and carba-
`prostacyclin (cPGI2) led to an increased blood flow as
`measured by laser Doppler flowmetry, in keeping with
`previous observations (Brain & Williams, 1989). CGRP837
`(400 nmol kg-', i.v.) had no significant effect on basal blood
`flow as shown in Figure 1. However, this figure shows that
`CGRP8-37 significantly inhibited the increased blood flow
`induced by CGRP but not that induced by the prostaglan-
`dins. These results indicate that the administration of int-
`ravenous CGRP8-37 can be used to investigate the release of
`vasoactive amounts of endogenous CGRP.
`The effect of the application of topical capsaicin on rat
`cutaneous blood flow is shown in Figure 2. Capsaicin in-
`creased blood flow in a dose-related manner, whilst the vehi-
`cle had no effect on blood flow when tested at the highest
`concentration used. The graph is similar to that obtained by
`Lynn and co-workers (1992). CGRP8-37 caused an almost
`
`T
`
`200 -
`
`150-
`
`0 -
`
`ooo100
`50
`
`.0
`
`CGRP
`(10 pmol)
`
`PGE,
`(300 pmol)
`
`cPG12
`(100 pmoI)
`
`-50L
`Figure I The effect of calcitonin gene-related peptide (CGRP) and
`vasodilator prostaglandins on blood flow in rat abdominal skin.
`Results are expressed as percentage change in local skin blood flow
`at each injected site compared with blood flow at the site before
`injection. The results from control rats (0.1% BSA, i.v.) are shown
`by the open columns and from rats
`treated with CGRP8.37
`(400 nmol kgT efi.v.) are shown by the solid columns. The results are
`expressed as the meanrs.e.mean of 9 rats in each group. A
`significant effect of CGRP8-37 on the vasodilator activity of CGRP is
`shown by *P<0.05.
`
`shaved and depilated. Thirty minutes later CGRP8-37 or vehi-
`cle were given i.v. and blood flow was measured at several
`sites with a laser Doppler flowmeter. Prostaglandins, CGRP
`or Tyrode were injected intradermally (50,l) and capsaicin
`or vehicle (20% alcohol: 10% Tween 80: 70% saline) were
`(5 tLI). Blood flow was measured again
`applied topically
`between 5-O min after application of test agents. Blood
`flow changes were measured with a Moor dual probe laser
`Doppler (MBF3D) and measured as flux, as previously dis-
`cussed in detail (Lawrence & Brain, 1992). The results are
`expressed as percentage change in blood flow compared with
`pre-injected sites in Figures 1 and 2. In some experiments the
`protocols were designed to measure responses to vasoactive
`agents and to saphenous nerve stimulation in the same
`animals.
`
`Measurement of bloodflow after saphenous nerve
`stimulation
`After induction of anaesthesia the hind limbs of the rat were
`shaved and depilated with a commercial cream. The jugular
`vein was cannulated for i.v. administration of anaesthetic and
`test agents. The saphenous nerves were carefully dissected in
`both legs (stimulated or sham legs) tied centrally, placed on
`bipolar platinum electrodes and immersed in mineral oil. In
`order to study antidromic vasodilatation one laser Doppler
`probe was positioned and secured over the hind paw skin in
`a region innervated by the saphenous nerve, i.e. medio-dorsal
`side of the skin of the hind paw, as confirmed by the
`observation of Evans Blue dye extravasation after saphenous
`nerve stimulation. The other probe was positioned in a cor-
`responding site on the sham treated hind paw to monitor
`basal blood flow throughout the experiment. Not earlier than
`preparation was finished,
`30 min after
`the
`antidromic
`stimulation was performed using the following parameters:
`10 V, 1 ms, 2 Hz for 30 s. Three stimulations were given at
`20-30 min intervals. To investigate the effect of CGRP8-37 on
`blood flow changes induced by saphenous nerve stimulation,
`CGRP837 (400 nmol kg-'), or vehicle (0.1% BSA in saline)
`were administered i.v. 5 min prior to the second stimulation.
`Results in Figure 3 show the flux in 3a and 3b; whilst Figure
`3c shows percentage change in the vasodilator response to
`saphenous nerve stimulation, after i.v. treatments.
`
`Measurement of oedema in the hind paw after saphenous
`nerve stimulation
`The saphenous nerves were prepared as described above and
`left for 5 min. Then Evans Blue (25 mg kg-') and '25I-labelled
`human serum albumin (50 kBq) were injected into the rat via
`the tail vein. CGRP8-37 (400 nmol kg-') or vehicle (0.1%
`BSA) were administered via the jugular vein, at least 5 min
`prior to stimulation. Then the nerve was stimulated: 1O V,
`1 ms, 2 Hz for 5 min. After stimulation, a blood sample was
`obtained by cardiac puncture and then the animal killed by
`anaesthetic overdose. The oedematous area of skin of the
`hind paw (as observed by Evans blue dye extravasation) was
`removed and weighed. An approximately equal amount of
`skin was also removed from the sham hind paw and weighed.
`Radioactivity was counted in 100 lAl of plasma and hind paw
`skin samples. Plasma extravasation was expressed as IL1 of
`plasma in 100 mg of skin and a ratio calculated: sham versus
`stimulated hind paw oedema for each rat.
`
`Statistical analysis
`Results are expressed as mean ± s.e.mean. Abdominal, dorsal
`skin and paw blood flow data were analysed by Bonferroni's
`modified t test, the standard error estimate for the analysis of
`variance was used to allow comparison of multiple sites. The
`significance of the hind paw skin oedema after saphenous
`nerve stimulation was tested by Student's unpaired t test.
`
`2
`
`

`

`10
`
`40
`30
`20
`Time (min)
`
`50
`
`60
`
`0
`
`b
`
`0
`
`10
`
`20 30 40 50 60
`Time (min)
`
`70
`
`r-
`
`M o1
`
`0, a
`
`40
`
`2
`
`3
`
`240
`
`200
`
`160
`
`120
`
`80
`
`40
`
`0
`
`240
`
`200
`
`160
`
`120
`
`80
`
`40
`
`0
`
`-40
`
`-80
`
`-1.
`
`x
`
`xL2
`
`0 V00 0
`
`)._
`
`Ca
`
`)
`o)
`
`Effect of CGRP8-37 on blood flow in the skin of rat hind
`Figure 3
`paw after saphenous nerve stimulation (10 V, 1 ms, 2 Hz, for 30 s).
`(a) Effect of repeated stimulations of the saphenous nerve on blood
`flow in the skin of a rat hind paw. The rat received vehicle (0.1%
`BSA in saline, i.v.) 5 min prior to the second stimulation. (b) Effect
`of CGRP8.37 (400 nmol kg-', i.v., 5 min before the second stimula-
`tion) on saphenous-induced blood flow in the rat hind paw skin. The
`results for (a) and (b) are expressed as Flux (arbitrary unit) and the
`dotted line indicates flux recorded on the contralateral paw. Stimula-
`tion of the saphenous nerve is represented by the upward arrows. (c)
`Collected results to show the effect of CGRP8-37 on blood flow
`induced by saphenous nerve stimulation. Results are expressed as
`percentage change in blood flow compared to the first stimulation
`and are the mean ± s.e.mean of 4 rats in each group. In each group
`CGRP8.37 or vehicle were administered i.v. at least 5 min prior to the
`second stimulation. CGRP8-37 inhibited blood flow after the second
`stimulation (*P< 0.05) and the third stimulation.
`
`plasma extravasation. In those experiments, blood flow was
`femoral
`measured
`by
`outflow.
`vein
`the
`In
`present
`experiments blood flow
`is measured by laser Doppler
`flowmetry. The use of the laser Doppler blood flow meter to
`measure saphenous nerve-stimulated increased blood flow
`was first used by Gamse & Saria
`(1987).
`It became
`immediately apparent that an increase in blood flow could be
`induced by a mild and short electrical stimulation when
`compared with the electrical stimulation necessary for the
`
`774
`
`K.J. ESCOTT & S.D. BRAIN
`
`Vehicle
`
`0.1
`
`10
`1
`Capsaicin (mM)
`
`33
`
`250
`
`200
`
`150
`
`100
`
`50
`
`0
`
`0 o0 a
`
`)
`a)a)
`c._,
`
`Figure 2 The effect of topical capsaicin on blood flow in rat
`abdominal skin. Results are expressed as percentage increase in local
`blood flow at each injected site compared with blood flow at the site
`before injection. The open columns represent control rats (0.1%
`BSA, i.v.) and the solid columns are animals treated with CGRP8-37
`(400 nmol kg-', i.v.). Each column is the mean ± s.e.mean of 9 rats.
`CGRP8-37 significantly inhibited the vasodilator activity of capsaicin
`at a dose of 10 nm, as shown by *P<0.05.
`
`total inhibition of blood flow induced by capsaicin (10 mM).
`However, little inhibitory effect of a higher dose of capsaicin,
`33 mM was observed.
`A short (30 s) electrical stimulation of the saphenous nerve
`caused an increased blood flow which returned to baseline
`levels within 5-O min after stimulation. This response was
`repeatable at least three times, as shown in Figure 3a.
`CGRP8-37 caused an inhibition of the peak response as
`shown in Figure 3b. The group data, with an inhibition of
`stimulated blood flow at both time points after saphenous
`nerve stimulation are shown in Figure 3c. No evidence of
`oedema formation was observed within this short stimulation
`period. By comparison increasing the stimulation period to
`5 min led to the well established neurogenic oedema forma-
`tion (shown in Figure 4) as first described by Jancso et al.
`(1967). The oedema was significantly attenuated by CGRP8-37.
`The results suggest that CGRP8-37 acted to inhibit approx-
`imately 50% of the oedema formation induced by electrical
`stimulation of the saphenous nerve.
`
`Discussion
`
`The results show that CGRP8-37 acts in a selective manner to
`antagonize the actions of exogenous CGRP in increasing
`blood flow. CGRP8.37 also significantly inhibited the in-
`creased blood flow induced by topical capsaicin (10 mM) and
`saphenous nerve stimulation, as well as oedema formation
`induced by saphenous nerve stimulation. CGRP8-37 failed to
`inhibit the increased blood flow induced by the highest dose
`of capsaicin (33 mM). The reason for this is unclear; possibly
`a maximal response combined with the release of increased
`levels of CGRP resulted in an inability of CGRP8-37 to inhibit
`the increased blood flow. Alternatively other vasodilator
`mediators might be involved in mediating the increased blood
`flow induced by this dose of capsaicin.
`The stimulation of the saphenous nerve in rats previously
`treated with guanethidine, to deplete a sympathetic compo-
`nent, has become an established small animal model of
`neurogenic inflammation, since Lembeck & Holzer (1979)
`provided evidence that substance P acts as a neurogenic
`of antidromic
`mediator
`neurogenic
`vasodilatation
`and
`
`3
`
`

`

`CGRP RELEASE FROM SAPHENOUS NERVE
`
`775
`
`1992). It is unlikely that substance P acts directly via NK,
`receptors to increase blood flow as the selective NK, receptor
`agonist, GR73632, does not increase blood flow in rat skin,
`although it has potent oedema inducing effects which are
`potentiated by CGRP (Birch et al., 1992; Richards et al.,
`is known that the selective NK, receptor
`1993). Further it
`antagonist RP67580 does not affect the increased blood flow
`induced by stimulation of the saphenous nerve at levels
`al.,
`to induce oedema formation (Shepheard et
`sufficient
`1992). Thus a vasodilator component is likely to be involved
`in the resulting oedema formation. There are several pos-
`sibilities as to the identity of this vasodilator. Firstly the
`increased blood flow could be totally induced by CGRP at
`concentrations that were not possible to antagonize in the
`present experiments when oedema formation occurs in res-
`ponse to a 5 min electrical stimulation period. It should be
`remembered that CGRP837 is a peptide antagonist which is
`poorly characterized whilst CP96345 and RP67580 are non-
`peptide structures, developed on the basis of their affinity and
`selectivity as NK, receptor antagonists. Alternatively it
`is
`possible that substance P is released from the saphenous
`nerve in sufficient quantities to stimulate mast cell degranula-
`tion and thus the release of the vasoactive amines histamine
`and 5-hydroxytryptamine (5-HT). This has been suggested by
`previous studies where evidence for the involvement of his-
`tamine and 5-HT has been obtained (Lembeck & Holzer,
`1979; Morton & Chahl, 1980). However this would appear
`unlikely as the amines do not participate in the oedema
`response which, as discussed above, is completely inhibited
`by NK, receptor antagonists. It is also possible that another
`distinct, perhaps novel vasodilator, in addition to CGRP, is
`released from sensory nerves upon saphenous nerve stimula-
`tion. This is the most exciting possibility but we have no
`evidence to date that this is so.
`We consider that the involvement of CGRP in neurogenic
`oedema formation is of interest. It has recently been demon-
`strated that the NK, receptor antagonist, RP67580, inhibits
`oedema formation in the rat dura induced by trigeminal
`nerve stimulation (Shepheard et
`al.,
`1993);
`a neurogenic
`model that is considered to be relevant to migraine in man.
`Also increased CGRP levels have been measured in venous
`blood samples taken from patients with migraine (Goadsby
`et al., 1990). As CGRP is colocalized with substance P it
`could be released in the rat dura in vasodilator amounts. It is
`not known whether the endogenous release of CGRP is
`pro-inflammatory in terms of vasodilatation or oedema for-
`mation in the rat dura; but our results obtained in this study
`would suggest that such a possibility may exist. However, it
`should also be pointed out that CGRP, at vasodilator doses,
`is anti-inflammatory in the hamster cheek pouch causing a
`clear
`inhibition of mediator induced oedema formation
`al.,
`(Raud et
`1991). Our studies suggest that this anti-
`inflammatory mechanism does not operate in rat skin or paw
`(Newbold & Brain, 1993); but the collected findings highlight
`the possibility that CGRP could well have multiple effects on
`the inflammatory response.
`In conclusion we have shown that CGRP8-37 inhibits
`vasodilatation induced by topical capsaicin and saphenous
`nerve stimulation in the rat and thus provide evidence that
`endogenous CGRP is the major vasodilator mediator in these
`models of neurogenic inflammation. CGRP837 also signifi-
`cantly inhibited neurogenic oedema formation induced by
`stimulation of the saphenous nerve. We consider this is good
`evidence to suggest that CGRP potentiates oedema forma-
`tion when co-released from sensory nerves with substance P.
`
`K.J.E. is the recipient of an MRC/Glaxo collaborative studentship.
`We thank Dr H. Connors and Dr D. Beattie from Glaxo Group
`research, U.K. for their helpful discussion and Dr U. Ney from
`Celltech, U.K. for the gift of the human a-CGRP.
`
`*
`
`4.0 r
`
`3.5 1-
`
`3.0
`
`2.5
`
`2.0
`
`1.5 p
`
`.In.
`
`E 0 C
`
`u
`
`I C
`
`ontrol
`
`1.0
`
`F- -
`
`0.5p-
`
`0.0o
`
`Effect of CGRP8-37 (400 nmol kg-', i.v.) on oedema forma-
`Figure 4
`tion after electrical stimulation of the saphenous nerve (10 V, I ms,
`2 Hz for 5 min). Results are expressed as the ratio of plasma ext-
`ravasation in the stimulated compared to the sham-treated hind paw
`skin. The dashed line at I indicates the basal level of plasma extra-
`vasation in unstimulated paws. Results are expressed as mean ± s.e.
`mean of 10 rats in each group. CGRP8-37 (solid column) significantly
`reduced plasma extravasation as indicated by *P <0.05, in com-
`parison to the control rats (0.1% BSA, i.v., open column).
`
`observation of oedema formation. The reason for this is not
`clear. It is probably related to the potency of endogenous
`CGRP as a vasodilator in skin. It is also possible that CGRP
`is released from A-delta fibres in addition to C-fibre nerves in
`initial saphenous nerve stimulation (Janig & Lisney, 1989).
`The present results are compatible with the suggestion that
`CGRP is the principle vasodilator released after mild and
`short stimulation of sensory nerves and this is in keeping
`with the findings of Delay-Goyet and co-workers (1992) who
`published a brief communication with similar findings whilst
`this study was in progress. They also investigated the effect of
`a neurokinin-l antagonist (RP67580) and showed that this
`had no effect on saphenous nerve stimulation-mediated
`changes in blood flow.
`Thus our findings indicate that CGRP mediates the in-
`crease in cutaneous blood flow observed with saphenous
`nerve stimulation. Results of previous studies in our group
`show that CGRP, does not act by itself to increase microvas-
`cular permeability, but as a consequence of its vasodilator
`activity potentiates oedema formation induced by mediators
`of increased microvascular permeability such as substance P
`and neurokinin A, in species that include the rat (Brain &
`1989). We therefore investigated whether
`Williams, 1985;
`affect oedema formation
`induced
`by
`CGRP8-37 could
`saphenous nerve stimulation. The results show an approx-
`imately 50% inhibition. Similar experimental protocols have
`been used to investigate the effect of recently developed
`non-peptide NK, receptor antagonists on oedema formation
`induced by saphenous nerve stimulation. CP96345 (Lembeck
`et al., 1992; Xu et al., 1992) and RP67580 (Garret et al.,
`1991) almost completely abolished oedema formation, whilst
`a NK2 receptor antagonist, MenlO207, had no inhibitory
`effect (Xu et al., 1992). These results are in keeping with the
`previous suggestion that the NK, receptor mediates increased
`microvascular permeability (Andrews et al., 1989). The par-
`tial inhibitory activity of CGRP837, on oedema formation
`induced by saphenous nerve stimulation,
`indicates
`that
`in neurogenic
`involved
`endogenously-released CGRP is
`oedema formation. An increase in blood flow is observed and
`this is concomitant with oedema formation (Shepheard et al.,
`
`4
`
`

`

`776
`
`K.J. ESCOTT & S.D. BRAIN
`
`References
`
`ANDREWS, P.V., HELME, R.D. & THOMAS, K.L. (1989). NK1 receptor
`mediation of neurogenic plasma extravasation in rat skin. Br. J.
`Pharmacol., 97, 1232-1238.
`BIRCH, P.J., HARRISON, S.M., HAYES, A.G., ROGERS, H. & TYERS,
`M.B. (1992). The non-peptide NK, receptor antagonist (± )-CP-
`96,345, produces antinociceptive and anti-oedema effects in the
`rat. Br. J. Pharmacol., 105, 508-510.
`BRAIN, S.D., CAMBRIDGE, H., HUGHES, S.R. & WILSONCROFT, P.
`(1992). Evidence that calcitonin gene-related peptide contributes
`to inflammation in the skin and joint. Proc. Natl. Acad. Sci.
`U.S.A., 657, 412-419.
`BRAIN, S.D. & WILLIAMS, T.J. (1985). Inflammatory oedema induced
`by synergism between calcitonin gene-related peptide (CGRP)
`and mediators of increased vascular permeability. Br. J. Phar-
`macol., 86, 855-860.
`BRAIN, S.D. & WILLIAMS, T.J. (1989). Interactions between the
`tachykinins and calcitonin gene-related peptide lead to
`the
`modulation of oedema formation and blood flow in rat skin. Br.
`J. Pharmacol., 97, 77-82.
`BRAIN, S.D., WILLIAMS, T.J., TIPPINS, J.R., MORRIS, H.R. & MACIN-
`TYRE, I. (1985). Calcitonin gene-related peptide is a potent
`vasodilator. Nature, 313, 54-56.
`CHIBA, T., YAMAGUCHI, A., YAMATANI, T., NAKAMURA, A.,
`MORISHITA, T., INUI, T., FUKASE, M., NODA, T. & FUJITA, T.
`peptide
`antagonist
`(1989).
`gene-related
`receptor
`Calcitonin
`human CGRP(8-37). Am. J. Physiol., 256, E331-E335.
`DELAY-GOYET, P., SATOH, H. & LUNDBERG, J.M. (1992). Relative
`involvement of substance P and CGRP mechanisms in antid-
`romic vasodilation in the rat skin. Acta. Physiol. Scand., 146,
`537-538.
`DONOSO, M.V., FOURNIER, A., ST-PIERRE, S. & HUIDOBRO-TORO,
`J.P. (1990). Pharmacological characterization of CGRP1 receptor
`subtype in the vascular system of the rat: studies with hCGRP
`fragments and analogs. Peptides, 11, 885-889.
`GAMSE, R. & SARIA, A. (1985). Potentiation of tachykinin-induced
`plasma protein extravasation by calcitonin gene-related peptide.
`Eur. J. Pharmacol., 114, 61-66.
`GAMSE, R. & SARIA, A. (1987). Antidromic vasodilatation in the rat
`hindpaw measured by laser Doppler flowmetry: pharmacological
`modulation. J. Auton. Nerv. Syst., 19, 105-111.
`GARDINER, S.M., COMPTOM, A.M., KEMP, P.A., BENNETT, T., BOSE,
`C., FOULKES, R. & HUGHES, B. (1990). Antagonistic effect of
`human a-CGRP[8-37] on the in vivo regional haemodynamic
`actions of human aCGRP. Biochem. Biophys. Res. Commun., 171,
`938-943.
`GARRET, C., CARUETTE, A., FARDIN, V., MOUSSAOUI, S.,
`PEYRONEL, J.-F., BLANCHARD, J.-C. & LADURON, P.M. (1991).
`Pharmacological properties of a potent and selective nonpeptide
`Natl. Acad. Sci.
`substance P antagonist.
`U.S.A., 88,
`Proc.
`10208-10212.
`GOADSBY, P.J., EDVINSSON, L. & EKMAN, R. (1990). Vasoactive
`peptide release in the extracerebral circulation of humans during
`migraine headache. Ann. Neurol., 28, 183-187.
`Inhibition of
`(1990).
`HAN, S.P., NAES, L. & WESTFALL, T.C.
`periarterial
`stimulation-induced
`vasodilatation of the
`nerves
`mesenteric arterial bed by CGRP(8-37) and CGRP receptor
`desensitization. Biochem. Biophys. Res. Commun., 168, 786-791.
`HUGHES, S.R. & BRAIN, S.D. (1991). A calcitonin gene-related pep-
`tide (CGRP) antagonist (CGRP8-37) inhibits microvascular re-
`sponses induced by CGRP and capsaicin in skin. Br. J. Phar-
`macol., 104, 738-742.
`
`HUGHES, S.R., BUCKLEY, T.L. & BRAIN, S.D. (1992). Olvanil: more
`potent than capsaicin at stimulating the efferent function of
`sensory nerves. Eur. J. Pharmacol., 219, 481-484.
`JANIG, W. & LISNEY, S.J.W. (1989). Small diameter myelinated
`afferents produce vasodilatation but not plasma extravasation in
`rat skin. J. Physiol., 415, 477-486.
`JANSCO, N., JANSCO-GABOR, A. & SZOLCSANYII, J. (1967). Direct
`evidence for neurogenic inflammation and its prevention by
`denervation and by pretreatment with capsaicin. Br. J. Phar-
`macol., 31, 138-151.
`LAWRENCE, E. & BRAIN, S.D. (1992). Responses to endothelins in
`the rat cutaneous microvaculature: a modulatory role of locally-
`produced nitric oxide. Br. J. Pharmacol., 106, 733-738.
`LEMBECK, F., DONNERER, J., TSUCHIYA, M. & NAGAHISA, A.
`(1992). The non-peptide tachykinin antagonist, CP-96,345, is a
`potent inhibitor of neurogenic inflammation. Br. J. Pharmacol.,
`105, 527-530.
`LEMBECK, F. & HOLZER, P. (1979). Substance P as neurogenic
`mediator of antidromic vasodilation and neurogenic plasma
`extravasation. Naunyn-Schmied Arch. Pharmacol., 310, 175-183.
`LYNN, B., YE, W. & COTSELL, B. (1992). The actions of capsaicin
`applied topically to the skin of the rat on C-fibre afferents,
`antidromic vasodilatation and substance P levels. Br. J. Phar-
`macol., 107, 400-406.
`(1980). Pharmacology of the
`MORTON, C.R. & CHAHL, L.A.
`neurogenic oedema response to electrical stimulation of the
`saphenous nerve in the rat. Naunyn-Schmied. Arch. Pharmacol.,
`314, 271-276.
`NEWBOLD, P. & BRAIN, S.D. (1993). The modulation of inflam-
`matory oedema by calcitonin gene-related peptide. Br. J. Phar-
`macol., 108, 705-710.
`RAUD, J., LUNDERBERG, T., BRODDA-JANSEN, G. THEODORSSON,
`E. & HEDQVIST, P. (1991). Potent anti-inflammatory action of
`calcitonin gene-related peptide. Biochem. Biophys. Res. Commun.,
`180, 1429-1435.
`RICHARDS, K.J., CAMBRIDGE, H. & BRAIN, S.D. (1993). Com-
`(NKI) receptor
`parative
`effects of a neurokinin- I
`agonist,
`GR73632, and CGRP on microvascular tone and permeability in
`rat skin. Neuropeptides, 24, 206.
`SHEPHEARD, S.L., COOK, D.A., WILLIAMSON, D.J., HURLEY, C.J.,
`HILL, R.G. & HARGREAVES, R.J. (1992). Inhibition of neurogenic
`plasma extravasation but not vasodilation in the hind limb of the
`rat by the non-peptide NK-1 receptor antagonist (+) RP 67580.
`Br. J. Pharmacol., 107, 150P.
`SHEPHEARD, S.L., WILLIAMSON, D.J., HILL, R.G. & HARGREAVES,
`R.J. (1993). The non-peptide neurokinin, receptor antagonist, RP
`67580, blocks neurogenic plasma extravasation in the dura mater
`of rats. Br. J. Pharmacol., 108, 11-12.
`XU, J.-X., DALSGAARD, J.-C., MAGGI, C.A. & WIESENFELD-HALLIN,
`Z. (1992). NK-1, but not NK-2, tachykinin receptors mediate
`plasma extravasation induced by antidromic C-fiber stimulation
`in rat hindpaw: demonstrated with the NK- 1 antagonist CP-
`96,345 and the NK-2 antagonist Men 10207. Neurosci. Lett., 139,
`249-252.
`
`(Received March 30, 1993
`Revised May 10, 1993
`Accepted May 18, 1993)
`
`5
`
`

`

`
`
`BIOCHEMISTRY AND MOLECULAR BIOLOGY OF NITRIC OXIDE
`
`
`
`
`
`SYMPOSIUM
`New and Emerging Mechanisms of Biosyntbesis, Metabolism, and Biological Actions of
`Nitric Oxide in Health and Disease
`
`July 16 - 21, 1994
`
`UCLA Sunset Village - Los Angeles, California
`Symposium Chairpersons — Louis J. Ignarro 0 Michael A. Marlena o Ferid Murad
`Symposium Advisors — Salvador Moncada . Solomon H. Snyder . John R. Vane
`
`Symposium Format
`° Continuous Plenary Sessions - invited speakers Iii/mm on tbe ltttic‘ltt’ttlt.\'l7_‘l’
`and molecular biology ofm‘tne oxide,
`' Poster Presentations - submitted abstracts in all fields (f basic
`and clinical research on nitric oxide
`- Special Plenary Session on Inbalational therapy will) Nitric Oxide
`
`Registration Fee $580
`Application pending for continuing medical education credit
`
`Forfmtber information please contact
`
`KREBS Convention Management Services 0 553 helium Street. Suite .200 0 Sztn Francisco, (LA 91' 10743548
`
`litx NH) 25"» 8100
`(415)253-l2‘fl
`
`
`i hllllll
`
`till pope“
`In respect ol
`IcpIIIIlIiIlIoII .iII' IescI\cIl
`\Il lll'llls III
`.IItIcles IllustI.IIIIIIIs, I'tt
`published III lllls lHllllltll III till kt’lllllllL'I
`Iil
`lltt' “Ulltl
`
`lllls iIIIIIII.I| I. pliilt'clt'tl l\\ IIIIIHII'hl
`III
`,\|| Ill.tlL‘t|.ll I‘lll‘llsllk'tl
`lll‘llls tII
`II'pIIIIlIIII
`illlsl
`‘llsllllilllt‘
`the
`\slIItli \t'\Cl\ L'\\l|l\l\l’
`III.Ichi.Il
`\IIIII.itI'II.Il Illll‘llsllt'tl Ill llils iIIIIIII.Il Ill.t's ltt'lt'|)11ttllll\"l
`III stoII-Il IIII IIIIIIIIIIIIII III
`III L'lL'LllltllIt
`lllllllill I'l
`iII.II'm'lH lt‘lttl
`\\|llll|lll llic \\l|llt'll .IIItlIorIs.ItIIIII IIt
`tliI
`l'lll‘llsllt'l
`
`III
`.I'
`II
`.‘\lllllt|ll/.lllllll to ttlItIlItLIIp) items lIII IIIteIII.Il III per IHIMl
`the IIIteIII.I|
`III
`[K'Isttllill use III spchlit
`tlICllls
`II emitted ll,
`Nltlklllllldll l’lt'ss I
`III
`IIII'
`|IliI.irIcs .IIId IItlII-I
`II-.I~Is IeIIIsteIeIl \\|lll
`lllt'
`( I-tutii'lil ( lciit.llitc ( cltlcl t( (
`(
`J
`llIIll's.“ IIIIII.Il choititii'
`Senice. pioutleil tlI.Il the lime Ice oi fist) til) per top; is [mill IlIII I tlx
`to (’( (
`.
`.‘l
`( oneiess Ht
`, Salem, MA ”W7”.
`l \c\
`
`I\p;nt lIoIII tlIIV ltlll tlt'.lltll}.‘ loI the pIII'pIIsc.IIt II-sc.IIIh III IIII\.III
`stud). III cIItIIIsIII III
`IL‘\IC\A.
`.Is pcIIIIItthI IIIIIch the ( IIIIIIII'lIl
`Designs .IIIIl l’.Itent «\tt
`I‘mK, this piililimtIIIII III.I) he H‘tiIIIIlIIII'd
`stored III
`tI.IIIsIIIIttI-Il. III .III\
`I‘oIIII t|l hi .iII\ IIIe.IIIs
`IIIle wtli llII-
`priol
`[lt'llllt‘sslttll
`III
`\t'IItIIIy II!
`the pIIlilIslII-Is
`III
`III
`the I.l\t'
`III
`It'lllltl’lilllllli
`Iepiotltiction,
`lll
`.II'cIIIIl.IIIce
`\sitli
`lllt'
`lt'lllII
`III
`licences Issued h}.
`the ('opiI'Ii-ht
`l ichisIIIII Aecnu
`
`The Britii'li JourIIu/ol I’IIIIrIiIIII 0/1th ts puhlishctl monthly hi the
`Scientific 45L MedIctIl l)I\IsIoII.
`t‘ldL'l

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket